Lv2
200 积分 2025-02-21 加入
AJCC Cancer Staging System Version 9: Practice-Informing Updates for Gastroenteropancreatic Neuroendocrine Tumors
1小时前
待确认
563P Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
11天前
已完结
[Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer
Based on Molecular Markers]
29天前
已完结
Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
4个月前
已完结
The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutations
8个月前
已完结
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
8个月前
已完结
Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
8个月前
已完结
EP.07E.03 TP53 Co-Mutations Increase Risk of Recurrence in EGFR-Mutated Stage I Lung Adenocarcinoma
8个月前
已关闭
Correlation Analysis of the TP53 Mutation With Clinical Characteristics in the Prognosis of Non–Small Cell Lung Cancer
8个月前
已完结
The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer
8个月前
已完结
皖公网安备34019202002308
